Post-earnings recap
Reported
Thu, Mar 24, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics reported a loss per share of $0.12, which was in line with expectations, but no revenue figures were provided. The stock fell by 6.18% following the earnings report, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's direction without specific targets or revenue updates.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.